Finally, a PD‐1–CD70 fusion protein has recently been described that can target tumour cells by blocking the PD‐1–PDL1 interaction and provide the missing CD70 activation signal to CD27+ T cells.56 This evidence concerns the gene CD27 and neoplasm.